---
figid: PMC5709276__nihms880760f1
figtitle: Pathway alterations in glioblastoma multiforme
organisms:
- NA
pmcid: PMC5709276
filename: nihms880760f1.jpg
figlink: /pmc/articles/PMC5709276/figure/F1/
number: F1
caption: 'Pathway alterations in glioblastoma multiforme. Canonical signaling pathway
  and tumor suppressor pathways are summarized for glioblastoma, highlighting potential
  nodes of convergence amenable to blockade by experimental therapeutics as monotherapy
  or in combination with radiation therapy. Percentages represent the proportion of
  glioblastoma cases harboring amplification (+) or mutation or homozygous deletion
  (−) of indicated pathway node. Figure adapted from reference []. Abbreviations:
  EGFR = epidermal growth factor receptor, PDGFT = platelet-derived growth factor
  receptor, c-MET = hepatocyte growth factor receptor, FGFR = fibroblast growth factor
  receptor, PTEN = phosphatase and tensin homolog, PI3K = phosphoinositide 3-kinase,
  NF1 = neurofibromatosis type 1, Akt = protein kinase B, mTOR = mammalian target
  of rapamycin, MAPK = mitogen-activated protein kinase, MDM2 = mouse double minute
  2 homolog, CDK = cyclin-dependent kinase, RNR = ribonucleotide reductase, Rb = retinoblastoma
  protein.'
papertitle: 'Radiation-agent combinations for glioblastoma: challenges in drug development
  and future considerations.'
reftext: Charles A. Kunos, et al. J Neurooncol. ;134(3):551-557.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.7858
figid_alias: PMC5709276__F1
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC5709276__F1
ndex: c6898ad2-df28-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5709276__nihms880760f1.html
  '@type': Dataset
  description: 'Pathway alterations in glioblastoma multiforme. Canonical signaling
    pathway and tumor suppressor pathways are summarized for glioblastoma, highlighting
    potential nodes of convergence amenable to blockade by experimental therapeutics
    as monotherapy or in combination with radiation therapy. Percentages represent
    the proportion of glioblastoma cases harboring amplification (+) or mutation or
    homozygous deletion (−) of indicated pathway node. Figure adapted from reference
    []. Abbreviations: EGFR = epidermal growth factor receptor, PDGFT = platelet-derived
    growth factor receptor, c-MET = hepatocyte growth factor receptor, FGFR = fibroblast
    growth factor receptor, PTEN = phosphatase and tensin homolog, PI3K = phosphoinositide
    3-kinase, NF1 = neurofibromatosis type 1, Akt = protein kinase B, mTOR = mammalian
    target of rapamycin, MAPK = mitogen-activated protein kinase, MDM2 = mouse double
    minute 2 homolog, CDK = cyclin-dependent kinase, RNR = ribonucleotide reductase,
    Rb = retinoblastoma protein.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - EGFR
  - FGFR1
  - FGFR2
  - FGFR3
  - FGFR4
  - FGFRL1
  - PTEN
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - KRAS
  - HRAS
  - NRAS
  - NF1
  - AKT1
  - AKT2
  - AKT3
  - BRAF
  - MTOR
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - MDM2
  - CDKN2A
  - CDKN2B
  - TP53
  - TP63
  - TP73
  - MDM4
  - CDK4
  - CDK6
  - NR2E3
  - Cancer
  - Lung cancer
  - Melanoma
---
